Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
| Common synonyms | GIP/GLP-1 dual agonist; LY3298176 | Development codes appear in earlier literature |
| Purity specification | Usually 95% or higher by HPLC area | Research-grade lots are often 98% or higher |
| Solution storage | 2–8 °C, protected from light | Short term; avoid repeated freeze-thaw cycles |
| Dry powder storage | −20 °C or below, desiccated | Protected from moisture and light |
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
=== Triplex forming oligonucleotides (TFO) === TFOs are short (≈15-25 nt) nucleic acid strands that bind in the major groove of double-stranded DNA to form intramolecular triplex DNA structures. There is some evidence that they are also able to modulate gene activity in vivo. In peptide nucleic acid (PNA), the sugar-phosphate backbone of DNA is replaced with a protein-like backbone. PNAs form P-loops while interacting with duplex DNA, forming a triplex with one strand of DNA while displacing the other. Very unusual recombination or parallel triplexes, or R-DNA, have been assumed to form under RecA protein in the course of homologous recombination. TFOs bind specifically to homopurine-homopyrimidine regions that are often common in promoter and intron sequences of genes, influencing cell signaling. TFOs can inhibit transcription by binding with high specificity to the DNA helix, thereby blocking the binding and function of transcription factors for particular sequences. By introducing TFOs into a cell (through transfection or other means), the expression of certain genes can be controlled. This application has novel implications in site-specific mutagenesis and gene therapy. In human prostate cancer cells, a transcription factor Ets2 is over-expressed and thought to drive forward the growth and survival of cells in such excess. Carbone et al. designed a sequence-specific TFO to the Ets2 promoter sequence that down-regulated the gene expression and led to a slowing of cell growth and cell death. Changxian et al.
== Biography == Robert Brownlee was born October 21, 1942, in South Dakota. He founded Brownlee Labs in the 1970s, in the San Francisco Bay area, a manufacturer of columns and pumps for high-performance liquid chromatography systems. Bob Brownlee took the initiative "along with Tom Jupille, Steve Bakalyar, Nelson Cooke, Jerry Higgins and Ron Majors" to form the Bay Area Chromatography Colloquium. Bob Stevenson is quoted as saying in his Nine Lives of the California Separation Science Society that Brownlee Labs was "certainly one of the globe's leaders in HPLC column technology." In the 1980s, when Robert Brownlee was diagnosed with AIDS-related complex, he sold his company to Applied Biosystems of Foster City, California, in 1984. (Applied later merged with Perkin-Elmer). Sometime later, he began a new company, which was viewed by Applied as a competitor. A lawsuit was instituted and later settled (Brownlee v. Applied Biosystems, Inc., 1989-1 Trade Cas. (CCH) ¶ 68, (N.D. Cal. 1989) 8,14). In 1990, he was interviewed for an article in The Scientist about Applied Biosystems. "If you produce the first product for these virgins [scientists without such equipment], you have a big value added, and you can charge a big price for your product," Brownlee says. "That's the reason Applied Biosystems did so well." He also formed the Robert Brownlee Foundation, a private family foundation which supports, with grants, K–12 science.
== Mechanism of action == Melanotan II acts as a non-selective agonist of the melanocortin receptors MC1, MC3, MC4, and MC5. Melanotan II produces melanogenesis by activation of the MC1 receptor, whereas its clinically documented sexual effects are thought to be related to its ability to activate the MC4 receptor (though the MC3 is thought to also possibly be involved). Melanotan II is partly metabolised into Bremelanotide, a medication used to treat low sexual desire. Other effects of melanotan II, mostly regarded as adverse effects, include flushing, nausea, vomiting, stretching, yawning, and loss of appetite (the last via activation of MC4).
Sources: en.wikipedia.org
=== Health history === A patient's health history may include disorders that affect the body's ability to heal itself. These disorders are called comorbidities and may interfere with circulatory and metabolic body functions, levels of various physiological assessment components (sugar, albumin, etc.), and induce other factors that negatively affect the healing. Common co-morbidities are: diabetes, venous insufficiency or peripheral arterial disease, respiratory and cardiovascular disorders, malignancies and autoimmune disorders.
== History == The concept of validation was first proposed by two Food and Drug Administration (FDA) officials, Ted Byers and Bud Loftus, in 1979 in USA, to improve the quality of pharmaceuticals. It was proposed in direct response to several problems in the sterility of large volume parenteral market. The first validation activities were focused on the processes involved in making these products, but quickly spread to associated processes including environmental control, media fill, equipment sanitization and purified water production. The concept of validation was first developed for equipment and processes and derived from the engineering practices used in delivery of large pieces of equipment that would be manufactured, tested, delivered and accepted according to a contract The use of validation spread to other areas of industry after several large-scale problems highlighted the potential risks in the design of products. The most notable is the Therac-25 incident. Here, the software for a large radiotherapy device was poorly designed and tested. In use, several interconnected problems led to several devices giving doses of radiation several thousands of times higher than intended, which resulted in the death of three patients and several more being permanently injured. In 2005 an individual wrote a standard by which the transportation process could be validated for cold chain products.
Freeman was cast at the suggestion of producer Liz Glotzer, despite the novella's character of a white Irishman. Filming proved to be challenging, mainly because of Darabont's need for multiple takes. Freeman said, "The answer [I'd give him] was no ... having to do something again and again for no discernible reason tends to be a bit debilitating to the energy." Nevertheless, his performance was described as "quietly impressive" and "moving" by The New York Times. At the 67th Academy Awards the film received Academy Award nominations for Best Picture and a nomination for Freeman for Best Actor losing to Tom Hanks in Forrest Gump (1994). Since its release, The Shawshank Redemption has remained popular among audiences. In 1994, Freeman served as a member of the jury at the 44th Berlin International Film Festival. Outbreak (1995), a medical thriller directed by Wolfgang Petersen, was Freeman's next film. He played General Billy Ford, a doctor dealing with an outbreak of a fictional virus in a small town. The film stars Dustin Hoffman, Rene Russo, and Donald Sutherland. Outbreak was a box-office success, grossing $189.8 million worldwide, but gained a mixed critics' response. Mick LaSelle of the San Francisco Chronicle credited Freeman for his performance which may have been unappreciated by viewers. In 1995, Freeman starred with Brad Pitt in David Fincher's crime thriller Seven, the story of two detectives who attempt to identify a serial killer who bases his murders on the Christian seven deadly sins.
Calendula () is a genus of about 15–20 species of annual and perennial herbaceous plants in the daisy family, Asteraceae that are often known as marigolds. They are native to Europe, North Africa, Macaronesia, West Asia and Western Himalayas and have their center of diversity in the Mediterranean Region. Other plants known as marigolds include corn marigold, desert marigold, marsh marigold, and plants of the genus Tagetes. The genus name Calendula is a modern Latin diminutive of calendae, meaning "little calendar", "little clock" or possibly "little weather-glass". The common name "marigold", a contraction of "Mary's gold" used especially for Calendula officinalis, refers to the Virgin Mary. C. officinalis is the most commonly cultivated and used species, popular herbal and cosmetic products named "Calendula" invariably derive from it.
Sources: en.wikipedia.org
Although the number of American teenagers who smoked cigarettes was steadily falling during the 2010s, the prevalence of electronic cigarette use was rising. As of 2019, there is no evidence linking the availability of electronic cigarettes to a decline in traditional smoking among youths. Public opinion has turned against electronic cigarettes and various state and local governments are seeking to restrict use. By the mid-2020s, tobacco product use of all types among teenagers was on the decline, a trend largely driven by falling e-cigarette demand. Bloomberg reported in 2019 that members of Generation Z were twice as likely as an average American to consume cannabis. About 1% of the number of legal marijuana consumers came this demographic cohort, and that number tripled in 2019. Generation Z is the first to be born into a time when the legalization of marijuana at the federal level is being seriously considered. As of 2019, cannabis is legal in 33 U.S. states as well as in Canada and Uruguay. Even though Generation Z may not think of cannabis as anything more than a controversial issue, there is mounting concern on its effects on human health. A survey of literature reveals that marijuana usage is linked to, among other things, impaired driving, higher risks of stroke, testicular cancer, memory loss, and certain mental illnesses, such as psychosis. Compared to those who do not use cannabis or those who start after they reach 16 years, people who start before that age suffer from reduced cognitive functioning and higher levels of impulsivity.
The AST/ALT ratio or De Ritis ratio is the ratio between the concentrations of two enzymes, aspartate transaminase (AST) and alanine transaminase, a.k.a. alanine aminotransferase (ALT), in the blood of a human or animal. It is used as one of several liver function tests, and measured with a blood test. It is sometimes useful in medical diagnosis for elevated transaminases to differentiate between causes of liver damage, or hepatotoxicity. Most causes of liver cell injury are associated with a greater increase in ALT than AST, but an AST/ALT ratio of 2:1 or greater is suggestive of alcoholic liver disease, particularly in the setting of an elevated gamma-glutamyl transferase. The AST/ALT ratio can also occasionally be elevated in a liver disease pattern in patients with nonalcoholic steatohepatitis, and it is frequently elevated in an alcoholic liver disease pattern in patients with hepatitis C who have developed cirrhosis. In addition, patients with Wilson's disease or cirrhosis due to viral hepatitis may have an AST that is greater than the ALT, though the ratio typically is not greater than two. When the AST is higher than ALT, a muscle source of these enzymes should be considered. For example, muscle inflammation due to dermatomyositis may cause AST > ALT. This is a good reminder that AST and ALT are not good measures of liver function when other sources may influence AST and/or ALT, because they do not reliably reflect the synthesizing ability of the liver, and they may come from tissues other than liver (such as muscle).
== Mass spectrometry == Lys-N is becoming a popular protease used for protein digestion in proteomics experiments. The combination Lys-N proteolytic peptides and mass spectrometry sequencing with ETD creates tandem mass spectra composed mostly of amino terminal peptide fragment ions. This fragmentation pattern facilitates the applicability of these spectra for de novo peptide sequencing.
This trend, along with advice from the Food and Drug Administration's attorneys that it could not win a First Amendment case on the issue, prompted the administration to issue new rules for television commercials in 1997. Instead of including the "brief summary" that took up a full page in magazine ads and would take too long to explain in a short television advertisement, drug makers were allowed to refer viewers to print ads, informative telephone lines, and websites, and to urge people to talk to their doctors if they wanted additional information. Schering-Plough invested US$322 million in Claritin direct-to-consumer advertising in 1998 and 1999, far more than any other brand. Spending on direct-to-consumer advertising by the pharmaceutical industry rose from US$360 million in 1995 to US$1.3 billion in 1998, and by 2006, was US$5 billion.
They found it rarely included effective methods, was mostly generic, and was rarely tailored to patients' existing knowledge and behaviours. 14 December A WHO study comprehensively estimates excess deaths from the COVID-19 pandemic during 2020 and 2021, concluding ~14.8 million excess early deaths occurred, reaffirming their prior calculations from May as well as updating them, addressing criticisms. These numbers do not include measures like years of potential life lost, far exceed the 5.42 million officially reported deaths, may make COVID-19 2021's leading cause of death, and are similar to the ~18 million estimated by another study (see 10 Mar). Microbiome research: Researchers report the discovery of a gut–brain connection in mice that regulates motivation for exercise and can enhance performance by augmenting dopamine signalling during physical activity. A microbiome-wide association study associates thirteen microbial taxa with depressive symptoms (6 Dec). Scientists report that and how – including transfer of mobile genetic elements and infant diet – the maternal microbiome shapes offspring gut microbiomes as fetus and infant (22 Dec). A first global review summarizes scarce data on a likely largely declining "experience of nature" and nature-disconnection which prior studies suggest have impacts on health and proenvironmental behavior.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection is the usual approach, frequently combined with mass spectrometry for identity. Purity is reported as the area percentage of the main peak. Related impurities eluting near the main peak are usually summed and reported separately.
Removing water slows hydrolysis and limits aggregation, so dry powder retains its quality attributes longer than a solution. Suppliers define a shelf life and retest date for the dried form at specified temperatures. Once dissolved, the practical working lifetime shortens considerably.
It generally lists appearance, identity by mass, purity by chromatography, water or residual solvent content, and the methods used. Storage recommendations and a retest date are commonly included. Values are reported against a supplier specification rather than a single universal standard.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.